|

PSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer

RECRUITINGN/ASponsored by Niguarda Hospital
Actively Recruiting
PhaseN/A
SponsorNiguarda Hospital
Started2026-10-01
Est. completion2028-08-31
Eligibility
Age18 Years – 85 Years
SexMALE
Healthy vol.Accepted

Summary

TACTIC-P is a single-center, prospective, single-arm study in 12 men with biopsy-proven prostate cancer and pelvic lymph-node uptake on preoperative PSMA PET, without bone or visceral metastases, who are scheduled for robot-assisted radical prostatectomy and extended pelvic lymph-node dissection. On the day of surgery, participants receive intravenous gallium-68 PSMA-11 followed by PET/CT and PSMA-radioguided surgery using a drop-in gamma probe. Resected prostate tumor, metastatic lymph-node tissue, and matched blood samples are used for high-dimensional immune profiling. The main goal is to determine whether functional pathogen-specific bystander tissue-resident T cells can be identified and quantitatively characterized in the primary tumor and/or metastatic lymph nodes. The study also evaluates immune features relevant to future personalized immunotherapy, the ability of PSMA-radioguided surgery to detect pathologically positive lymph nodes, and perioperative safety through 12 weeks after surgery.

Eligibility

Age: 18 Years – 85 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Male participants.
* Age 18 to 85 years.
* Biopsy-proven prostate cancer with positive lymph nodes on staging PSMA PET (miN+).
* Planned robot-assisted radical prostatectomy with extended pelvic lymph-node dissection.
* Able to understand and willing to sign written informed consent.

Exclusion Criteria:

* Neoadjuvant hormonal therapy before surgery.
* Inability to complete imaging examinations according to the protocol.
* Bone or visceral metastatic disease (M1b-c) on preoperative imaging.
* Life expectancy \<12 months.
* Previous chemotherapy.
* Previous brachytherapy or external-beam radiotherapy.
* Congestive heart failure.
* Any other significant disease/disorder that, in the investigator's opinion, may increase risk, influence study results, or impair participation.
* History of allergic disease/reactions likely to be exacerbated by study IMPs or radiotracer components (68Ga-PSMA).
* Experimental drug within 30 days before radiotracer administration or within 5 half-lives of that experimental drug.

Conditions2

CancerProstate Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.